5-Methylcytosine Analysis of miRNAs in Minimal Change Disease

Area of Science:

• Nephrology
• Molecular Biology
• RNA Biology

Background:

• Minimal change disease (MCD) is a leading cause of nephrotic syndrome in children, with increasing adult prevalence.
• Noncoding RNAs, including microRNAs (miRNAs), undergo modifications like m5C during synthesis, influencing gene expression.
• Understanding miRNA modifications in MCD is crucial for identifying new diagnostic and therapeutic strategies.

Purpose of the Study:

• To investigate the role of N6-methyladenosine (m5C)-modified miRNAs in Minimal Change Disease (MCD).
• To identify potential biomarkers and therapeutic targets for MCD patients based on m5C-modified miRNA profiles.
• To elucidate the specific pathogenic mechanisms involving m5C-modified miRNAs in MCD.

Main Methods:

• Differential analysis of m5C-modified miRNAs in MCD patient samples.
• Bioinformatics analysis to predict the functional roles and targets of differentially modified miRNAs.
• Investigation of interactions between m5C writers, miRNAs, and target genes.

Main Results:

• A significant number of differentially m5C-modified miRNAs were identified in MCD patients, predominantly showing decreased modification.
• Specific miRNAs, including miR-1282, miR-340-3p, miR-526b-3p, miR-3925-3p, and miR-511-5p, exhibited differential modification.
• Downregulated m5C modification of miR-511-5p was linked to MCD pathogenesis, potentially via lipid metabolism dysregulation through reduced ENPP4 and ENTPD1 expression.

Conclusions:

• m5C-modified miRNAs play a pathogenic role in Minimal Change Disease.
• The overall m5C modification of miRNAs in MCD is downregulated, likely due to reduced DNMT1 activity.
• Downregulated miR-511-5p contributes to MCD by affecting metabolic pathways and downregulating ENPP4 and ENTPD1 expression, highlighting its potential as a therapeutic target.